This complete absence of tolerability-driven discontinuations represents a remarkable safety finding and indicates that even when mild side effects occurred, they were sufficiently manageable that participants chose to continue treatment
Their research guidelines page is a solid resource too: it covers proper storage (temperature/light/moisture control), labeling for traceability, structural notes (e.g., DAC vs non-DAC), and quality verification, all reinforcing best practices that align perfectly with careful reconstitution
Much of the purported clinical utility is derived from anecdotal accounts or small, uncontrolled series, rather than from robust randomized trials
Receptor activity-modifying proteins
Potential side effects (rare but possible): Injection site reactions (redness, mild swelling) Water retention with growth hormone peptides Temporary insulin sensitivity changes Mild headaches or fatigue during initial weeks What actually matters for safety: Source quality : Pharmaceutical-grade peptides from FDA-registered compounding pharmacies only